Targeting the dopaminergic midbrain with precision 7-Tesla biofeedback training in depression: A proof-of-principle randomized controlled trial
In brief
7-Tesla fMRI biofeedback lifts depressive mood for 24 hours
In a randomized trial of 62 unmedicated adults, active 7-Tesla fMRI neurofeedback targeting the dopaminergic midbrain produced a measurable improvement in depressed mood and negative affect immediately after training and still at 24 hours, but the benefit faded by one week. The intervention also strengthened ventral tegmental area-frontal connectivity, suggesting a mechanistic link, yet larger studies are needed to confirm durability.
- Journal
- Molecular psychiatry (Q1)
- Published
- 19 September 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Laurel S Morris, Jacqueline M Beltrán, Timo L Kvamme, Avijit Chowdhury, Grace Butler, Abigail Adams, et al.
- PMID
- 42763338
- DOI
- 10.1038/s41380-026-03911-x
Why clinicians should know about it
- Picked for Psychiatry and Mental Health (paper of the day, 21 September 2026): 7‑T fMRI biofeedback RCT for depression motivation
Abstract
The significant heterogeneity of major depressive disorder (MDD) requires the development of interventions that directly target underlying cognitive or neurobiological mechanisms. This work tested the efficacy of self-modulation of the dopaminergic midbrain with high-field 7-Tesla functional MRI biofeedback in a randomized, controlled, proof-of-principle trial that targeted motivation regulation. A total of N = 62 unmedicated participants (MDD and healthy controls) were randomized to receive either Active or Sham 7-Tesla functional MRI biofeedback and completed clinical assessments pre- and up to 30-days post-training. Factor analysis of clinical symptom change revealed a single latent clinical improvement factor that was significantly improved in the Active MDD compared to the Sham MDD group, immediately post-training (β = 15.85, t = 2.31, p = 0.03), and at 24-hours post-training (β = 22.84, t = 2.45, p = 0.02); effects were diminished and no longer significant at 7-day and 30-day follow-ups. Results of specific phenotypic clinical analysis revealed that depressed mood (F = 5.04, p = 0.029) and negative affect (F = 5.21, p = 0.027), but not positive affect, were most improved by the Active biofeedback intervention. Active biofeedback training engaged functional coupling over time between the VTA and the lateral frontal cortex in the MDD group (F = 6.03, p = 0.017), and greater overall VTA regulation was associated with clinical improvement (R = 0.268, p = 0.048). Together, these results indicate the potential utility of dopaminergic midbrain-based biofeedback training for improvement of mood and negative affect in MDD.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.